George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
I seriously hope this is not the case here given the sell of shares by BOD at a better price that we are today and their taking money from the HNWIs investment
August 19th RNS
Salary Deferral Scheme
The salary deferral scheme, as announced by the Company on 17 December 2019 and updated on 1 July 2020, will end in August 2021, with a total of £155k, representing all amounts outstanding, being settled in cash, following the significant c.£4.5m improvement in the Company's financial position arising from the recent share subscriptions and warrant exercise.
If so this leads to criminal charges in which following the addition of PH as joint broker and the sp demise stinks.
We are OWED a BOD response FACT!
Potnak this re submarine patent
USPTO
25 March 2021
U.S. patent application number 17/108266 was filed with the patent office on 2021-03-25 for pharmaceutical compounds. This patent application is currently assigned to Sareum Limited. The applicant listed for this patent is Sareum Limited. Invention is credited to John Charles READER
And this
Remember a submerged submarine patent when partially released...any future competitve approved products have a very very hard time to prove they did not 'borrow' the patent. We receive payments and royalties.
They even also mentioned that the improved 1802 patent upgrade adds value to Sareum's ipr!
When you read what was said in the RNS re £1m @ 8.25p this sp drop imo definitely deserves a BOD RNS response. Just read it below....they pretty much justify the third HNWI buy in price
Dr Tim Mitchell, CEO of Sareum Holdings plc, said: "This new subscription is Sareum's fourth since 1 June this year, reflecting the strong and continuing interest in our proprietary TYK2/JAK1 development programmes in autoimmune diseases, including the immune overreaction to Covid-19, and cancer. With the funds raised during this period now totalling over £4.5 million, our financial position has been significantly strengthened.
So why would the last 3 subscriptions above this sp which Sareum were happy to accept as a worthwhile buy in price not lead to the BOD dropping a tweet or RNS re this drop. Or have PH locked them in a room with no media access?
Surely the BOD have to release a RNS regarding this price as they accepted 3 further subscriptions above this price at 4.9p 7p and 8.25p thus surely intimating that is what our sp should be!?
Or am i missing something?
Appointment of Joint Corporate Broker
Cambridge, UK, 29 October 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce the appointment of Peel Hunt LLP as a Joint Corporate Broker with immediate effect. Strand Hanson Limited and Hybridan LLP will continue to act as the Company's Nominated Adviser and Joint Corporate Broker, respectively.
So they are 'pleased'.
As soon as investors of which ever stature see that PH are involved they realise things are occurring.
Why would you implement a joint corporate broker...well this re brokers...
Larger companies often appoint two brokers, building a relationship with both on a day-to-day basis, and are likely to use both in the event of a large transaction. ... Further, brokers' sales and research teams, who have close relationships with institutional investors, provide a vital source of feedback for the company.
I read the posters with great interest re institutional investors being made aware and let's not forget the Edison report was not a slow day at their office and did a report on a whim.
Definitely a concerted effort to cause discern here.
I'm holding and added last week.
Best regards Steadydanny
RMM. Amen. Brilliant.
Night HBD. When or if you get the time just read our RNSs 26th March 2020 and 8th January 2021.
Look at the time lines. It's all in the detail. 9 months! Anyhow happy to be invested here.
I apologise in advance HBD but this is long but myself and my partner were amade aware of this before the pandemic by a friend who is a professor of medicine back in 2019. Just look up Lieber and what happened. It got buried.
Harvard University Professor and Two Chinese Nationals Charged in Three Separate China Related Cases | OPA
www.justice.gov
The Department of Justice announced today that the Chair of Harvard University’s Chemistry and Chemical Biology Department and two Chinese nationals have been charged in connection with aiding the People’s Republic of China.
Dr. Charles Lieber, 60, Chair of the Department of Chemistry and Chemical Biology at Harvard University, was arrested this morning and charged by criminal complaint with one count of making a materially false, fictitious and fraudulent statement. Lieber will appear this afternoon before Magistrate Judge Marianne B. Bowler in federal court in Boston, Massachusetts.
Yanqing Ye, 29, a Chinese national, was charged in an indictment today with one count each of visa fraud, making false statements, acting as an agent of a foreign government and conspiracy. Ye is currently in China.
Zaosong Zheng, 30, a Chinese national, was arrested on Dec. 10, 2019, at Boston’s Logan International Airport and charged by criminal complaint with attempting to smuggle 21 vials of biological research to China. On Jan. 21, 2020, Zheng was indicted on one count of smuggling goods from the United States and one count of making false, fictitious or fraudulent statements. He has been detained since Dec. 30, 2019.
Dr. Charles Lieber
According to court documents, since 2008, Dr. Lieber who has served as the Principal Investigator of the Lieber Research Group at Harvard University, which specialized in the area of nanoscience, has received more than $15,000,000 in grant funding from the National Institutes of Health (NIH) and Department of Defense (DOD). These grants require the disclosure of significant foreign financial conflicts of interest, including financial support from foreign governments or foreign entities. Unbeknownst to Harvard University beginning in 2011, Lieber became a “Strategic Scientist” at Wuhan University of Technology (WUT) in China and was a contractual participant in China’s Thousand Talents Plan from in or about 2012 to 2017. China’s Thousand Talents Plan is one of the most prominent Chinese Talent recruit plans that are designed to attract, recruit, and cultivate high-level scientific talent in furtherance of China’s scientific development, economic prosperity and national security. These talent programs seek to lure Chinese overseas talent and foreign experts to bring their knowledge and experience to China and reward individuals for stealing proprietary information. Under the terms of Lieber’s three-year Thousand Talents contract, WUT paid Lieber $50,000 USD per month, living expenses of up to 1,000,000 Chinese Yuan (approximately $158,000 USD at the time)
Hi HBD. This why toxicology is important re pharmacology
With human monitoring studies, toxicology provides important information to both medicine and epidemiology. It contributes to a better understanding of disease etiology, such as that of cancer, and the plausibility of the causal association between disease development and the exposure to hazard agents.
I'm going to touch on getting into the conversation of experimental 'vaccines' until 2023 that are allowed rapid approval without any manufacturers or government liability.
We are going by the book. Lots of other 'drugs' have been fast tracked. Maybe just maybe given the ineffectiveness of the 'vaccines' requiring a second and then a booster and then a further one (yes my missus hasn't seen one of her daughters or parents in HK since Dec 2019 but was nearly hospitalised when visiting hk in Dec 2019 with 'flu' but requires 3 weeks quarantine if she visits now £8k!! Quarantine!!....surely an ongoing developing and non-rushed alternative is of relevance?
I am very perplexed by the decisions that some countries are taking in lockstep. Imagine that your ability to see a daughter or parent abroad required a vaccine passport. And vice a versa.
Very worried. But hopefully we can assist a form of normality. Trust me our conversations re travel and meeting loved ones seems we have been separated indefinitely.
Scott. Great points. I'm still looking at the language in our RNSs
Dr Tim Mitchell, CEO of Sareum Holdings plc, said: "This new subscription is Sareum's fourth since 1 June this year, reflecting the strong and continuing interest in our proprietary TYK2/JAK1 development programmes in autoimmune diseases, including the immune overreaction to Covid-19, and cancer. With the funds raised during this period now totalling over £4.5 million, our financial position has been significantly strengthened and we are looking forward to completing the preclinical studies with SDC-1801 and advancing it into clinical development, and to progressing the preclinical development of our second TYK2/JAK1 inhibitor SDC-1802."
And then a bit later I believe 30rh July
Sareum's CSO, Dr John Reader, commented:
"The granting of this patent in the US will provide a further layer of protection around SDC-1802 following the granting of patents protecting the molecule in the US and other major markets in recent years. These patents are important to enhancing the value of the programme as part of our discussions with potential partners."
Potential partners continuously mentioned. Q and A mentioned rapid development of 1802 due to similar pathway. Why would we upgrade patents if we were flogging a dead horse?
Money in the bank. Patents improved globally. Going to clinical with 1801 . 1802 will piggy back on this.
Hi Silverfoil. So why did the BOD allow HNWIs to invest at 7p and 8.25p? To make themselves a laughing stock of a company that tricks people by allowing said individuals to overpay on what ipr we have that justified the market capital valuation at the time of subscriptions and for them to invest?
We wanted the funds to (imo) give ourselves a better bartering position with licenses. Since that others caught on and wanted to wear down pis.
The HNWIs would surely have some type of fraudulent valuation part of their agreement with Sareum re their buy in price if the ipr and mc didn't match up.
My hunch when we say keeping 'potential partners' updated on progress but we never hear who they are.
A question that would do well at the AGM is are you under any NDAs but cannot mention potential partners?
Re should the board say something re these drops well YES plain and simply.
The HNWIs subscriptions are as
1st June £900k @ 2.8p
15th June £1.47m @ 4.9p
14th July £180k first sub warrants exercised
19th July £1m @ 7p
Then £1m @ 8.25p.
So the BOD are hardly going to want to lose industry standing and credibility by shafting the HNWIs and accepting their money without qualifying that especially the last one is that we are worth 8.25p a share with a 10.25p warrant options.
So we should be at 8.25p minimum!!!!
Reeks of manipulation by mms.
Took x5 requotes as the price kept rising!!
Hi Celtic. Primarily we do not hold the reigns on this drug but we do have very reasonable returns after first administration including royalties. Regards 737 first off our BOD were pleased with the new employee recruitment at Sierra looking at their pipeline drugs earlier this year.
Then 29th September
Sareum's CEO, Dr Tim Mitchell, commented:
"This timeline for the possible initiation of combination studies by Sierra including SRA737 in the first half of 2022 is very encouraging and would represent a significant advance in the development of the SRA737 programme. We look forward to further updates on the clinical development of SRA737, a molecule that has shown great promise in clinical trials and preclinical studies, particularly in combination with other types of cancer therapy."
Then our Q and A response from Tim re 100% 737 positive response in lung cancer.
I personally wonder if Sierras fundraiser has consideration towards 737. I think so!
I'm still expecting an update from our BOD regards the conference today.
I'm personally of the opinion that the recent renegotiation was a means to garner a means of ....give us a bit back and then we will deliver.
As in bartering.
Just my opinion.
This from our Chairman 25th October
We are pleased to report that we are approaching an important milestone with SDC-1801, the start of human clinical development, targeting autoimmune diseases.
As noted in the Company's Trading Update of 19 August 2021, we expect to complete the toxicology studies required for this phase of the preclinical programme for SDC-1801 by the end of 2021 and have initiated the process to manufacture drug product for clinical trials.
So this is news which would give 'potential partners' their investment decision.
Later on he said
In terms of business development, we are continuing to keep potential partners informed of our progress with a view to securing commercial licences for our TYK2/JAK1 programmes that balance cost and risk with maximising shareholder value. We will, as usual, keep shareholders updated in this regard as appropriate.
The subscriptions and Edison report I cannot see as just fanciful whims.
I'm guessing the toxicology is showing promise and when that news is released this year then I suspect we will see a long overdue positive sp response.
I am wary of posters who make cynical and derogatory posts without validating it with anything of comparison to our progress, uniqueness, forward looking objectives and last but by no means last ....the actual science and patents (note recent additions).
Or maybe they just choose to ignore the positives.
Absolutely agree Ahfam.....and the Edison report was not because they were just bored.
Fair shout James. I'm awaiting the outcome of the Sierra conference tomorrow with baited breath. Tim would not in a RNS vis a vi a Q and A later on mention his noteable excitement unless the BOD with their again noteable experience feel that such a response was required or appropriate.
1801 is walking the walk. 1802 follows a similar pathway. Submarine patent and updated US patent protection approved and previous one submerged.
US Sierra at a conference tomorrow.
Boom!
Sierra attending a conference tomorrow. Want to raise money. Q and A mentioned 100% response in lung cancer trials using SRA737.
Tim was noteably excited about the Sierra response.
I think they are as sat on the edge of their seats as we are but there has definitely been an increase in our RNSs mentioning 737. They know the science. Just wait. Friday or Monday update incoming.
Appreciate we have had indifferences James and maybe I get a bit agitated. I apologise about that. But just look up the PH postings re Novacyt and what happened before the extraordinary rise.. they were a bit tricky in their updates but they definitely got income. And that was about a test. Not various treatments re cytokine storms etc
Sincerely best regards.
One thing I'm certain of is that we will have an update either this Friday or Monday coming as Sierra released this on the 12th November and we pretty much always follow up on a Sierra conference et al ...
....announced the company will participate in the 2021 Jefferies London Healthcare Conference. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra, will provide an overview of the company in a presentation that will be available on demand beginning at 8:00 am GMT (3:00 am ET) on Thursday, November 18, 2021, to conference attendees.
We know they are raising funds and I'm sure this platform will be their positive findings and potential and as Tim mentioned re 737 100% in Q and A.
As others have pointed out Sareum is a tight lipped ship regards 'leaks'. Maybe not elsewhere?Given I believe we as shareholders are only as aware of any information from Sierra as the board are due to our interest as a part owner in SRA737.
Does make you wonder the last few weeks sp shenanigans here are not by chance.
Watching with interest.